References
- Brunning R D, Matutes E, Borowitz M J, . Acute leukemias of ambiguous lineage. Pathology and genetics of tumours of the haematopoietic and lymphoid tissues, J W Vardiman, et al. IARC Press, LyonFrance 2001; 106–107
- Bene M C, Castoldi G, Knapp W, Ludwig W D, Matutes E, Orfao A, van't Veer M B. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783–1786
- Killick S, Matutes E, Powles R L, Hamblin M, Swansbury J, Treleaven J G, et al. Outcome of biphenotypic acute leukemia. Haematologica 1999; 84: 699–706
- O'Dwyer M E, Mauro M J, Druker B J. STI571 as a targeted therapy for CML. Cancer Invest 2003; 21: 429–438
- Kurzrock R, Kantarjian H M, Druker B J, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003; 138: 819–830
- Ottmann O G, Druker B J, Sawyers C L, Goldman J M, Reiffers J, Silver R T, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965–1971
- Thomas D A, Faderl S, Cortes J, O'Brien S, Giles F J, Kornblau S M, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103: 4396–4407
- Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004; 104: 3507–3512
- Lee K H, Lee J H, Choi S J, Lee J H, Seol M, Lee Y S, et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005; 19: 1509–1516
- Selle B, Bar C, Hecker S, Schmidt-Rohr U, Viehmann S, Debatin K M, Reinhardt D. ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL). Leukemia 2002; 16: 1393–1395
- Martin S E, DellaValla J. Untreated essential thrombocythemia evolving to biphenotypic leukemia, Philadelphia chromosome positive with monosomy 7: response to imatinib and reduced-intensity allogeneic stem cell transplant. Leukemia 2005; 19: 1095–1096
- Kolb E A, Pan Q, Ladanyi M, Steinherz P G. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. Cancer 2003; 98: 2643–2650
- Faderl S, Jeha S, Kantarjian H M. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003; 98: 1337–1354
- Rajappa S, Uppin S G, Raghunadharao D, Rao I S, Surath A. Isolated central nervous system blast crisis in chronic myeloid leukemia. Hematol Oncol 2004; 22: 179–181
- Rytting M E, Wierda W G. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy. Leuk Lymphoma 2004; 45: 1623–1626
- Petzer A L, Gunsilius E, Hayes M, Stockhammer G, Duba H G, Schneller F, et al. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 2002; 117: 623–625